Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
08 2019
Historique:
received: 07 01 2019
accepted: 26 03 2019
pubmed: 11 5 2019
medline: 17 4 2020
entrez: 11 5 2019
Statut: ppublish

Résumé

Around 5%-10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA). We aimed to assess pathophysiological mechanisms in MINOCA by extensively evaluating cardiovascular biomarkers in the stable phase after an event, comparing MINOCA patients with cardiovascular healthy controls and MI patients with obstructive coronary artery disease (MI-CAD). Ninety-one biomarkers were measured with a proximity extension assay 3 months after MI in 97 MINOCA patients, 97 age- and sex-matched MI-CAD patients, and 98 controls. Lasso analyses (penalized logistic regression models) and adjusted multiple linear regression models were used for statistical analyses. In the Lasso analysis (MINOCA vs MI-CAD), 8 biomarkers provided discriminatory value: P-selectin glycoprotein ligand 1, C-X-C motif chemokine 1, TNF-related activation-induced cytokine, and pappalysin-1 (PAPPA) with increasing probabilities of MINOCA, and tissue-type plasminogen activator, B-type natriuretic peptide, myeloperoxidase, and interleukin-1 receptor antagonist protein with increasing probabilities of MI-CAD. Comparing MINOCA vs controls, 7 biomarkers provided discriminatory value: N-terminal pro-B-type natriuretic peptide, renin, NF-κ-B essential modulator, PAPPA, interleukin-6, and soluble urokinase plasminogen activator surface receptor with increasing probabilities of MINOCA, and agouti-related protein with increasing probabilities of controls. Adjusted multiple linear regression analyses showed that group affiliation was associated with the concentrations of 7 of the 8 biomarkers in the comparison MINOCA vs MI-CAD and 5 of the 7 biomarkers in MINOCA vs controls. Three months after the MI, the biomarker concentrations indicated greater inflammatory activity in MINOCA patients than in both MI-CAD patients and healthy controls, and a varying degree of myocardial dysfunction among the 3 cohorts.

Sections du résumé

BACKGROUND
Around 5%-10% of patients with myocardial infarction (MI) present with nonobstructive coronary arteries (MINOCA). We aimed to assess pathophysiological mechanisms in MINOCA by extensively evaluating cardiovascular biomarkers in the stable phase after an event, comparing MINOCA patients with cardiovascular healthy controls and MI patients with obstructive coronary artery disease (MI-CAD).
METHODS
Ninety-one biomarkers were measured with a proximity extension assay 3 months after MI in 97 MINOCA patients, 97 age- and sex-matched MI-CAD patients, and 98 controls. Lasso analyses (penalized logistic regression models) and adjusted multiple linear regression models were used for statistical analyses.
RESULTS
In the Lasso analysis (MINOCA vs MI-CAD), 8 biomarkers provided discriminatory value: P-selectin glycoprotein ligand 1, C-X-C motif chemokine 1, TNF-related activation-induced cytokine, and pappalysin-1 (PAPPA) with increasing probabilities of MINOCA, and tissue-type plasminogen activator, B-type natriuretic peptide, myeloperoxidase, and interleukin-1 receptor antagonist protein with increasing probabilities of MI-CAD. Comparing MINOCA vs controls, 7 biomarkers provided discriminatory value: N-terminal pro-B-type natriuretic peptide, renin, NF-κ-B essential modulator, PAPPA, interleukin-6, and soluble urokinase plasminogen activator surface receptor with increasing probabilities of MINOCA, and agouti-related protein with increasing probabilities of controls. Adjusted multiple linear regression analyses showed that group affiliation was associated with the concentrations of 7 of the 8 biomarkers in the comparison MINOCA vs MI-CAD and 5 of the 7 biomarkers in MINOCA vs controls.
CONCLUSIONS
Three months after the MI, the biomarker concentrations indicated greater inflammatory activity in MINOCA patients than in both MI-CAD patients and healthy controls, and a varying degree of myocardial dysfunction among the 3 cohorts.

Identifiants

pubmed: 31072836
pii: clinchem.2018.301085
doi: 10.1373/clinchem.2018.301085
doi:

Substances chimiques

AGRP protein, human 0
Agouti-Related Protein 0
Biomarkers 0
IKBKG protein, human 0
Interleukin-6 0
PLAUR protein, human 0
Peptide Fragments 0
Receptors, Urokinase Plasminogen Activator 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0
I-kappa B Kinase EC 2.7.11.10
Renin EC 3.4.23.15

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1023-1030

Informations de copyright

© 2019 American Association for Clinical Chemistry.

Auteurs

Marcus Hjort (M)

Department of Medical Sciences, and marcus.hjort@medsci.uu.se.
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Kai M Eggers (KM)

Department of Medical Sciences, and.

Lars Lindhagen (L)

Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Stefan Agewall (S)

Institute of Clinical Sciences, Oslo University Hospital, University of Oslo, Oslo, Norway.

Elin B Brolin (EB)

Department of Clinical Science, Intervention and Technology.

Olov Collste (O)

Department of Clinical Sciences and Education, Södersjukhuset.

Maria Daniel (M)

Department of Clinical Sciences and Education, Södersjukhuset.

Christina Ekenbäck (C)

Department of Clinical Sciences, Division of Cardiovascular Medicine, Danderyd Hospital.

Mats Frick (M)

Department of Clinical Sciences and Education, Södersjukhuset.

Loghman Henareh (L)

Heart and Vascular Theme, Department of Medicine, Karolinska University Hospital, and.

Claes Hofman-Bang (C)

Department of Clinical Sciences, Division of Cardiovascular Medicine, Danderyd Hospital.

Karin Malmqvist (K)

Department of Clinical Sciences, Division of Cardiovascular Medicine, Danderyd Hospital.

Jonas Spaak (J)

Department of Clinical Sciences, Division of Cardiovascular Medicine, Danderyd Hospital.

Peder Sörensson (P)

Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

Shams Y-Hassan (S)

Heart and Vascular Theme, Department of Medicine, Karolinska University Hospital, and.

Per Tornvall (P)

Department of Clinical Sciences and Education, Södersjukhuset.

Bertil Lindahl (B)

Department of Medical Sciences, and.
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH